Literature DB >> 17972276

The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls.

Colin Palmer1, Kathryn A Ellis, Barry V O'Neill, Rodney J Croft, Sumie Leung, Chris Oliver, Keith A Wesnes, Pradeep J Nathan.   

Abstract

N-methyl-D-aspartate (NMDA) receptors play an important role in learning and memory. Targeting the glycine modulatory site of the NMDA receptor has been suggested as a therapeutic strategy to improve cognition, although findings have not been convincing. We used the Cognitive Drug Research computerised assessment system to examine the effects of high-dose glycine on a number of cognitive processes in healthy young subjects. The study was a randomised placebo controlled repeated measures design in which each subject received acute placebo or glycine (0.8 g/kg) orally, with treatment conditions separated by a 5-day washout period. No significant effects of glycine were found on measures of working memory, declarative memory, attention or perceptual processing. These findings, together with those of previous studies, cast doubt over the ability of acute high-dose glycine to improve cognitive function in healthy subjects and suggest that the optimum dose of glycine for improving cognition may vary between different populations, possibly due to differences in endogenous glycine levels and the functional status of NMDA receptors. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17972276     DOI: 10.1002/hup.904

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

Review 1.  Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge.

Authors:  Frank Petrat; Kerstin Boengler; Rainer Schulz; Herbert de Groot
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans.

Authors:  Barry V O'Neill; Rodney J Croft; Sumie Leung; Chris Oliver; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2007-07-24       Impact factor: 4.530

3.  The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice.

Authors:  Philipp Singer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2008-08-29       Impact factor: 4.530

4.  Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects.

Authors:  Robert W Schmidt; Meghan L Thompson
Journal:  Ment Health Clin       Date:  2016-11-03

Review 5.  NMDAR Hypofunction Animal Models of Schizophrenia.

Authors:  Gloria Lee; Yi Zhou
Journal:  Front Mol Neurosci       Date:  2019-07-31       Impact factor: 5.639

Review 6.  Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.

Authors:  Andrea de Bartolomeis; Mirko Manchia; Federica Marmo; Licia Vellucci; Felice Iasevoli; Annarita Barone
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.